Chan Soon-Shiong Nanthealth Foundation

THE SPECIFIC AND PRIMARY PURPOSE OF THIS ORGANIZATION IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS.

THE ORGANIZATION IS DIRECTLY ENGAGED IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH VARIOUS CLINICAL SETTINGS AND HOSPITALS. INITIALLY, THE ORGANIZATION WAS ENGAGED IN A JOINT EFFORT WITH PROVIDENCE SAINT JOHN'S HEALTH CENTER TO CONDUCT RESEARCH AND DEVELOPMENT OF PERSONALIZED MOLECULAR MEDICAL THERAPIES FOR THE TREATMENT OF UNMET MEDICAL NEEDS. CURRENTLY, THE ORGANIZATION IS ENGAGED IN JOINT EFFORTS WITH WINDBER HOSPITAL AND JOHNS HOPKINS UNIVERSITY TO CONDUCT PARALLEL RESEARCH AND DEVELOPMENT. THE ORGANIZATION PROVIDES FUNDING, DATA AND EXPERTISE AND PERFORMS SUPPORT SERVICES INCLUDING, WITHOUT LIMITATION, CUSTOM ENGINEERING, REGULATORY AND MEDICAL SUPPORT SERVICES FOR EACH PROJECT CONDUCTED THROUGH ITS JOINT EFFORTS WITH WINDBER HOSPITAL AND JOHNS HOPKINS UNIVERSITY. THE ORGANIZATION ALSO PLANS TO CONDUCT MEDICAL RESEARCH PROJECTS IN COLLABORATION WITH VARIOUS UNIVERSITIES, PARTICULARLY RESEARCH PROJECTS LED BY FACULTY OF THE UNIVERSITY OF CALIFORNIA AND PARTNER INSTITUTIONS. THE ORGANIZATION WILL ANNUALLY EXPEND FUNDS EQUAL TO 3.5% OR MORE OF THE FAIR MARKET VALUE OF ITS ENDOWMENT FOR THE CONTINUOUS CONDUCT OF MEDICAL RESEARCH OR WILL DEVOTE MORE THAN ONE HALF OF ITS ASSETS TO THE CONTINUOUS CONDUCT OF MEDICAL RESEARCH. ON 6/23/2020, A FINAL REPORT WAS ISSUED TO THE ORGANIZATION WITH RESPECT TO RESEARCH CONDUCTED BY MARK KELLY, M.D. REGARDING CERTAIN SIGNIFICANT ASPECTS OF UROLOGICAL ONCOLOGY, PARTICULARLY, THE TREATMENT AND MANAGEMENT OF PROSTATE CANCER. THE RESEARCH WAS INITIATED BY AN AGREEMENT MADE AND EFFECTIVE AS OF OCTOBER 15, 2018. A STEERING COMMITTEE WAS ESTABLISHED TO OVERSEE THE RESEARCH PROJECT AND QUARTERLY MEETINGS WERE HELD BY AND BETWEEN MARK KELLY, M.D. AND THE MEMBERS OF THE STEERING COMMITTEE DURING THE TERM. DR. KELLYS RESEARCH HOPES TO DETERMINE WHETHER MRIS AND OTHER BIOMARKERS CAN BE USED TO IDENTIFY WHICH PATIENTS WITH ELEVATED PSA LEVELS CAN BE TREATED WITH CRYOABLATION TO AVOID ADVERSE SIDE-EFFECTS OF OTHER LESS LOCALIZED COURSES OF TREATMENT.

THE ORGANIZATION IS CONDUCTING AND HOSTING AN ANNUAL HEALTH SUMMIT, CALLED "BREAKTHROUGHS IN MEDICINE," TO EXPLORE, ENGAGE AND DISCUSS CURRENT ISSUES AT THE INTERSECTION OF TECHNOLOGY AND HEALTHCARE, INCLUDING THROUGH ROUNDTABLE DISCUSSIONS. BREAKTHROUGHS IN MEDICINE IS AN EXCLUSIVE EVENT WITH LEADERS, INNOVATORS, INFLUENCERS AND VISIONARIES IN THE INDUSTRY IN ATTENDANCE. THE ORGANIZATION WILL ANNUALLY EXPEND FUNDS EQUAL TO 3.5% OR MORE OF THE FAIR MARKET VALUE OF ITS ENDOWMENT FOR THE CONTINUOUS CONDUCT OF MEDICAL RESEARCH OR WILL DEVOTE MORE THAN ONE HALF OF ITS ASSETS TO THE CONTINUOUS CONDUCT OF MEDICAL RESEARCH.